MDM2 and cancer: In addition, data from the Cancer Therapeutics Response Portal (CTRP) database of the Broad Institute indicate that LTβR expression is negatively correlated with the efficacy of certain anti-cancer drugs, including doxorubicin (topoisomerase II inhibitor) and nutlin-3a (MDM2 inhibitor).